Vitamin D deficiency increases body sway and decreases muscle mass and strength, increasing falls risk. 3, 4 Vitamin D supplementation reduces falls by 11% to 22%. 5, 6 To our knowledge, no studies have been conducted that report characteristics of ambulatory fallers associated with meeting the recommended adequate intake (RAI) of vitamin D. Patient characteristics associated with vitamin D intake in a falls study are reported.
METHODS
Data were analyzed from Safety Assessment for Elders (SAFE), a randomized, controlled study of multifactorial interventions to reduce falls (ClinicalTrials.org identifier NCT00140322). Eligible subjects were adults aged 65 and older at high falls risk. 7 At baseline and study end, researchers visited subjects' homes to examine all medication and supplement bottles and record vitamin D intake.
Participants were randomized to receive mailed home safety information or a multifactorial intervention designed to decrease falls risk. In the active arm, subjects with a daily vitamin D intake less than 800 IU were asked to increase intake to ! 800 IU per day. 8 Participants and their physicians received letters instructing them how to increase vitamin D intake. Participants were called monthly for 11 months to encourage adherence with recommendations.
Study outcomes were the rates and patient characteristics (Table 1 ) associated with meeting the age-specific vitamin D RAI of 400 IU per day for people aged 51 to 70 or 600 IU per day for people aged 71 and older 9 at study entry and study end. Subjects with unknown vitamin D intake at baseline (n 5 18 of 500) were excluded. Forty-five of 482 subjects had missing data at 1 year; these individuals were similar to the remaining subjects (P4.05, candidate variables).
All data were analyzed using Analyze-It software (Leeds, UK) and summarized using means AE standard deviations or percentages. Continuous study data were parametric, allowing analysis using independent sample t-tests. Chi-square tests examined proportions. In all cases, twosided Po.05 determined significant findings.
RESULTS
Vitamin D intake was recorded at baseline (n 5 482) and study end (n 5 446) from 500 subjects enrolled. Baseline demographics (Table 1 ) included a mean age AE standard deviation of 79 AE 8 and a predominance of female (75%) and Caucasian (97%) subjects. Participants reported an average of three falls yearly and a mean vitamin D supplement intake of 370 AE 320 IU daily. Only 28% of subjects met the vitamin D RAI at study entry, increasing to 37% at study end (P 5.007).
Five characteristics were associated with greater likelihood of meeting the age-specific vitamin D RAI at baseline (Table 1) . Participants meeting the RAI (n 5 135) were younger (76 AE 8 vs 80 AE 7, Po.001); had better physical function scores (41 AE 11 vs 39 AE 10, P 5.04); and were more likely to be female (87 vs 70%, P 5.003), to have had a prior fracture (47% vs 37%, P 5.05), and to take calcium supplements (94 vs 57%, Po.001).
Subjects with known vitamin D intake at entry and study end (n 5 437) increased vitamin D intake during the study (350 AE 300 IU/d to 410 AE 350 IU/d, P 5.009). Subjects randomized to active falls interventions (33 vs 17%, Po.001) and those reporting regular exercise (2 vs 20%, P 5.04) were statistically more likely to increase vitamin D intake during the 1-year study.
DISCUSSION
Vitamin D is a safe, inexpensive strategy to reduce falls and associated medical costs. This study showed that older fallers have a low rate of meeting the vitamin D RAI, especially men, older individuals, those without prior fracture, and those not taking calcium supplements. Patients and providers need greater education on the importance of vitamin D for prevention of falls and fractures. Written instructions and regular telephone follow-up appear to increase vitamin D intake in elderly fallers. This finding, if verified in additional studies, may prove an effective public health strategy
PIOGLITAZONE IMPROVED COGNITION IN A PILOT STUDY ON PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT WITH DIABETES MELLITUS
To the Editor: Accumulating evidence suggests that the insulin resistance and peripheral hyperinsulinemia associated with type II diabetes mellitus (DM) promote Alzheimer's disease (AD) pathogenesis. 1 Pharmacological treatment with thiazolidinedions such as rosiglitazone and pioglitazone, agonists of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARg), may offer some therapeutic relief of AD by lowering peripheral insulin and enhancing insulin sensitivity. In addition, PPARg agonists have been shown to reduce beta-amyloid accumulation and inflammatory reactants and exhibit neuroprotective effects. 2 It was recently demonstrated that 6 months of treatment with rosiglitazone preserved cognitive function in patients with AD and amnestic mild cognitive impairment (MCI), 3, 4 although there has been no report examining the effects of pioglitazone on cognitive function in patients with AD. The present study was designed to determine whether pioglitazone would have beneficial effects in patients with AD and MCI with type II DM.
This was a prospective randomized, open-controlled study. Thirty-two patients with mild to moderate AD (Mini-Mental State Examination (MMSE) score of 16-26) and amnestic MCI who were treated with oral hypoglycemic medications or diet for type II DM were enrolled after providing informed consent. Each diagnosis was made using the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria 5 for probable AD (26 patients) and Petersen's criteria 6 for amnestic MCI (6 patients). Subjects using insulin were excluded. Patients were randomly assigned to treatment with pioglitazone 15 to 30 mg daily (n 5 15, pioglitazone group) or not (n 5 17, control group) in addition to their previous treatment for control of DM. Patients taking donepezil (a cholinesterase inhibitor) were enrolled, provided that the dose had remained unchanged from 6 months before participation through study completion. No subjects were taking any medication known to affect cognition or behavior during the study. Changes from baseline to Month 6 in the MMSE, Alzheimer's Disease Assessment ScaleFCognitive Subscale Japanese version (ADAS-Jcog), and Wechsler Memory ScaleFRevised (WMS-R) logical memory-I were assessed. Additional measures included fasting plasma glucose
